Article
Infectious Diseases
Jin Shang, Huan Liu, Qin Wen, Rili M. Ise, You Tu, Lang Bai, Hong Tang
Summary: In this study, nucleos(t)ide analogue therapy with TDF was found to be more effective than LDT during pregnancy in women with chronic hepatitis B, and showed no evidence of renal toxicity. The use of nucleos(t)ide analogue therapy during pregnancy did not significantly impact the long-term physical development and bone development of children.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Gastroenterology & Hepatology
Jia-Horng Kao, Wen-Juei Jeng, Qin Ning, Tung-Hung Su, Tai-Chung Tseng, Yoshiyuki Ueno, Man-Fung Yuen
Summary: Chronic HBV infection is currently incurable and long-term treatment with NAs can reduce complications, but stopping treatment may lead to virological relapse and adverse outcomes. Close monitoring and personalized follow-up strategies are essential for a safe cessation of NA therapy.
HEPATOLOGY INTERNATIONAL
(2021)
Letter
Gastroenterology & Hepatology
Yao-Chun Hsu, Mindie H. Nguyen, Chun-Ying Wu
Summary: This article is linked to papers by Hsu et al. To view these articles, please visit and browse.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Gastroenterology & Hepatology
Yan Xue, Meng Zhang, Tao Li, Feng Liu, Li-Xin Zhang, Xiao-Ping Fan, Bao-Hua Yang, Lei Wang
Summary: In HBeAg-positive CHB patients with HBeAg loss, the consolidation period and HBsAg level at cessation were significant predictors of virological relapse after discontinuation of NAs. Patients with HBeAg seroconversion had lower cumulative relapse rates. Careful monitoring, especially in the early stages after cessation, may lead to a favorable outcome.
WORLD JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Gastroenterology & Hepatology
Florian van Boemmel, Kerstin Stein, Renate Heyne, Joerg Petersen, Peter Buggisch, Christoph Berg, Stefan Zeuzem, Andreas Stallmach, Martin Sprinzl, Eckart Schott, Anita Pathil-Warth, Ulrike von Arnim, Verena Keitel, Juergen Lohmeyer, Karl-Georg Simon, Christian Trautwein, Andreas Trein, Dietrich Hueppe, Markus Cornberg, Frank Lammert, Patrick Ingiliz, Reinhart Zachoval, Holger Hinrichsen, Alexander Zipprich, Hartmuth Klinker, Julian Schulze zur Wiesch, Anett Schmiedeknecht, Oana Brosteanu, Thomas Berg
Summary: Stopping NUC treatment can achieve a higher rate of HBsAg loss compared to continued treatment, especially for patients with end of treatment HBsAg levels <1,000 IU/ml.
JOURNAL OF HEPATOLOGY
(2023)
Article
Medicine, General & Internal
Guichan Liao, Xia Ding, Muye Xia, Yin Wu, Hongjie Chen, Rong Fan, Xiaoyong Zhang, Shaohang Cai, Jie Peng
Summary: This study showed that EOT HBcrAg level can predict off-treatment relapse in CHB patients, and an HBcrAg level of 4.0 log(10) U/mL may identify patients at high risk of clinical relapse after treatment cessation.
INTERNATIONAL JOURNAL OF GENERAL MEDICINE
(2021)
Article
Gastroenterology & Hepatology
Lung-Yi Mak, Danny Wong, Alison Kuchta, Martina Hilfiker, Aaron Hamilton, Ning Chow, XianHua Mao, Wai Kay Seto, Man-Fung Yuen
Summary: This study investigated the dynamics of serum HBV pre-genomic RNA (pgRNA) and hepatitis B core-related antigen (HBcrAg) in patients receiving nucleos(t)ide analogues (NAs) and their predictability for favourable suppression of serum hepatitis B surface antigen (HBsAg). The results showed that early on-treatment changes of serum HBV pgRNA and HBcrAg at 4 weeks can predict HBsAg seroclearance or <100 IU/mL in NA-treated CHB patients upon long-term follow-up.
CLINICAL AND MOLECULAR HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Spilios Manolakopoulos, Hariklia Kranidioti, Anastasia Kourikou, Melanie-Maria Deutsch, Christos Triantos, Chrysostomos Tsolias, Emanuel K. Manesis, Nicoletta Mathou, Alexandra Alexopoulou, Emilia Hadziyannis, George Papatheodoridis
Summary: The study showed that it is safe to discontinue nucleos(t)ide analogues therapy in non-cirrhotic patients with HBeAg-negative chronic hepatitis B. Over a median follow-up of more than 5 years, half of the patients remained without retreatment, with a substantial proportion achieving functional cure.
LIVER INTERNATIONAL
(2021)
Article
Immunology
Shi Liu, Rui Deng, Bin Zhou, Xieer Liang, Zhihong Liu, Jie Peng, Jinjun Chen, Yuanping Zhou, Yabing Guo, Yongpeng Chen, Wanying Li, Sheng Shen, Xingyu Lu, Siru Zhao, Xingmei Liao, Hongyan Liang, Yu Lan, Jinlin Hou, Rong Fan, Jian Sun
Summary: High levels of serum HBV RNA are associated with increased risk of hepatocellular carcinoma in chronic hepatitis B patients. Achieving undetectable HBV RNA may be a valuable endpoint of antiviral treatment.
JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Medicine, General & Internal
Yachao Tao, Menglan Wang, Juan Liao, Xing Cheng, Min He, Dongmei Zhang, Taoyou Zhou, Jie Chen, Enqiang Chen, Hong Tang
Summary: This study found that serum pgRNA levels were strongly correlated with HBV DNA and HBsAg levels. Low levels of serum pgRNA before treatment may indicate a high probability of HBeAg seroconversion. The baseline serum pgRNA level could serve as a novel predictor for HBeAg seroconversion.
FRONTIERS IN MEDICINE
(2022)
Article
Infectious Diseases
Guichan Liao, Ziying Liu, Muye Xia, Hongjie Chen, Houji Wu, Bing Li, Tao Yu, Shaohang Cai, Xiaoyong Zhang, Jie Peng
Summary: The significance of circulating soluble PD-1 (sPD-1) in patients with chronic hepatitis B who have discontinued long-term nucleos(t)ide analog (NA) treatment remains unknown. This study aimed to investigate the importance of sPD-1 levels in predicting clinical relapse and HBsAg loss after treatment discontinuation in patients with chronic hepatitis B. The results showed that sPD-1 levels at the end of treatment can be used to predict clinical relapse and HBsAg loss, and may help guide the treatment plan for patients with chronic hepatitis B virus infection.
INFECTION AND DRUG RESISTANCE
(2022)
Review
Public, Environmental & Occupational Health
Mian Wang, Mingxia Qian, Rongrong Fu, Yiqin Zhang, Xinlan Shen, Dengyuan Yue, Ning Wang, Lei Yang
Summary: This study compared the long-term outcomes between CHB patients who discontinued nucleos(t)ide analogs therapy and those who continued it, revealing that off-therapy patients had a higher risk of ALT flares-up and virological abnormalities. However, there were no significant differences in hyperbilirubinemia, hepatic decompensation, and HCC development between the two groups.
FRONTIERS IN PUBLIC HEALTH
(2021)
Article
Gastroenterology & Hepatology
Fumitaka Suzuki, Tetsuya Hosaka, Yoshiyuki Suzuki, Hitomi Sezaki, Norio Akuta, Shunichiro Fujiyama, Yusuke Kawamura, Satoshi Saitoh, Yasuji Arase, Mariko Kobayashi, Hiromitsu Kumada
Summary: Patients with chronic hepatitis B (CHB) who achieved HBsAg seroclearance after nucleos(t)ide analog (NA) therapy rarely experienced virological or clinical relapse after treatment cessation.
JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Biochemistry & Molecular Biology
Jyun-Yi Wu, Yi-Shan Tsai, Chia-Chen Li, Ming-Lun Yeh, Ching- Huang, Chung-Feng Huang, Jia-Ning Hsu, Meng-Hsuan Hsieh, Yo-Chia Chen, Ta-Wei Liu, Yi-Hung Lin, Po-Cheng Liang, Zu-Yau Lin, Wan-Long Chuang, Ming-Lung Yu, Chia-Yen Dai
Summary: This study aimed to investigate the association between serum miR-125b and liver fibrosis progression in chronic hepatitis B (CHB) patients after nucleos(t)ide analog (NA) treatment. The results showed that baseline miR-125b levels were inversely correlated with the post-treatment FIB-4 index. Age, baseline platelet level, and ALT level were identified as independent predictors of higher FIB-index after 12-month treatment. In patients receiving entecavir (ETV) monotherapy, the alteration of serum miR-125b and age were significantly associated with higher post-treatment FIB-4 index.
Article
Medicine, General & Internal
Julian Hercun, Theo Heller, Jeffrey S. Glenn, David E. Kleiner, Christopher Koh
Summary: This study evaluates the impact of nucleos(t)ide analogs on the histological appearance of chronic HDV infection and finds that patients on nucleos(t)ide analogs demonstrate a unique membranous staining pattern.
FRONTIERS IN MEDICINE
(2023)